Abstract: A coenzyme Q10 slow-release drug includes an isolation layer and a drug layer, where the drug layer is composed of coenzyme Q10 and a pharmaceutically acceptable carrier; the isolation layer is composed of a degradable gel; a diameter of the drug layer is not larger than that of the isolation layer. The coenzyme Q10 slow-release drug is prepared as follows. (S1) The degradable gel is laid on a mold for casting into a film to form the isolation layer. (S2) Coenzyme Q10 and the pharmaceutically acceptable carrier are mixed and laid on the mold in step (S1) for casting to form the drug layer on the isolation layer. (S3) Steps (S1) and (S2) are repeated, and then edges of adjacent controlled-release layers are bonded to obtain the coenzyme Q10 slow-release drug.

Abstract: Provided herein is a compound which is particularly suitable for use as a cannabinoid, as an emulsifier for a cannabinoid, in a formulation comprising the compound and in a method of treatment using the compound. The compound is defined by the General Formula: wherein: R1-R10 are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene; R11 and R12 are independently H or —(CH2CHR16O)x—R17 with the proviso that at least one of R11 or R12 represents —(CH2CHR16O)xR17—; R11 and R10 may be taken together to represent —C(R19)2—; R13-R15 independently represent H or an alkyl of 1-8 carbons; each R16 independently represents H or an alkyl of 1-3 carbons; each R17 independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid; each R19 independently represents H or an alkyl of 1-5 carbons; and each x is independently an integer of 1-100.

Abstract: Disclosed herein is a medical device for extended release of drugs. The device comprises a stent embedded with one or more drug depots that release of a therapeutic agent in a controlled manner. Each end of the stent may contain one or more anchors or attachment points which enable self-retention of the medical device once properly placed. The disclosed device further comprises a biosensor to monitor physiological characteristics like, e.g., intraocular pressure (IOP).

Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome and a therapeutic agent for treating dementia with a high drug to lipid ratio and a high encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the therapeutic agent. Also provided is the method for treating dementia using the pharmaceutical composition disclosed herein.

Abstract: The present invention relates to filamentous, i.e. thread-like nanoparticles comprising sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin. More particularly, the invention relates to the use of said thread-like nanoparticles in vaccines and drug delivery or adsorption systems systems, methods for their production and uses thereof, such as for use as a vaccine adjuvant and in cancer therapy.

Abstract: The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

Abstract: Embodiments provide a pest control agent that is excellent in safety, controlling effect, residual activity, and so on.

Abstract: Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Abstract: Embodiments of the present disclosure relates to commercial manufacturing process of making bupivacaine multivesicular liposomes with improved yield and desired particle size distribution.

Abstract: In an embodiment, a method to enhance a non-surgical medical treatment, the method including applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment, where the applying is at least one of before, during, and after the non-surgical medical treatment, beginning the non-surgical medical treatment to the area of skin, and continuing the non-surgical medical treatment until the non-surgical medical treatment is completed. In some embodiments, the antifibrinolytic agent is tranexamic acid in an amount of about 20% (w/v). In some embodiments, the method further includes minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment. In an additional embodiment, the present disclosure relates to a composition to enhance a non-surgical medical treatment, the composition having an antifibrinolytic agent. In a further embodiment, the present disclosure relates to a kit having a carrier and an antifibrinolytic agent.

Abstract: Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: This invention concerns a process for making a lyophilized pharmaceutical formulation of a therapeutic protein, which comprises (a) providing a formulation of a bulk amount of the therapeutic protein, (b) measuring the concentration of the therapeutic protein in said bulk formulation, (c) adjusting the fill weight of the protein in said bulk formulation to achieve a fixed dose of the protein, and (d) lyophilizing the protein fill weight-adjusted formulation to achieve a final formulation in a container, wherein the product concentration post reconstitution with a fixed volume is within a predetermined acceptance range. The process is particularly suitable for formulations with low protein concentrations (e.g., 0.05 mg/mL to 20 mg/mL).

Abstract: The present invention relates to sunscreen or daily care compositions comprising butyl methoxydibenzoylmethane, at least one UV filter selected from triazine derivatives, at least one photostabilizer selected from butyl octyl salicylate, benzotriazolyl dodecyl p cresol, ethyl hexyl methoxycrylene, polyester-8, diethyl hexyl syringylidenemalonate, trimethoxybenzylidene pentanedione, diethylhexyl 2,6-naphthalate, a fused ring cyanoacrylate derivative and polyester-25, wherein the composition does not comprise octocrylene and ethyl hexyl methoxy cinnamate.

Abstract: An object is to provide a dried amniotic membrane that promotes regeneration of a tendon and a tendon sheath when a tendon injury has occurred and that reduces loss of the motor function of fingers of upper limbs and lower limbs due to tendon adhesion as a novel regeneration material.

Abstract: This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.

Abstract: A novel ROS-responsive prodrug is provided. The prodrug utilizes a unique modified oxalate linker conjugated to 4-aminophenol, which can enhance the reaction kinetics for intracellular ROS within tumor tissues while keeping the modified oxalate backbone stable with amide bond under very low ROS level.

Abstract: The present invention relates to sunscreen or daily care composition comprising (i) hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate); and (ii) 1-(4-(1,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1,3-dione (INCI butyl methoxydibenzoylmethane); and (iii) 2,4-bis-{[4-(2-ethy-hexyoxy)-2-hydroxy]-pheny}-6-(4-methoxypheny)-1,3,5 triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine); and (iv) 4,4?,4?-(1,3,5-triazine-2,4,6-triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone) and/or 4, 4?-[[6-[[4-[[(1,1-dimethylethyl)amino]carbonyl]phenyl]amino]-1,3,5-triazin-2,4-diyl]diimino]bis-benzoic acid-bis(2-ethylhexyl)ester (INCI diethyl-hexyl-butamidotriazone); and (v) at least one organic particulate UV filter, wherein the composition is free of ethylhexyl-2-cyano-3, 3-diphenyl-acrylate (INCI octocrylene), 2-ethylhexyl-(2E)-3-(4-methoxyphenyl) acrylate (INCI ethylhexyl methoxy cinnamate) and pp benzylidene malonates, and wherei

Abstract: Provided is a method for prevention or treatment of a lysosomal storage disorder, and more particularly, to a method that may exhibit excellent efficacy against various lysosomal storage disorders including Niemann-Pick disease by including graphene quantum dots.

Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.

Abstract: There is disclosed a formulation suitable for the reduction or prevention of contamination of articles by microorganisms. The formulation includes at least one block copolymer of ethylene oxide and propylene oxide, at least one polyacrylic acid salt, and at least one propoxylated ethylenediamine compound.